Dietary phosphorus and kidney disease

Annals of the New York Academy of Sciences

Volumn 1301, Issue 1, 2013, Pages 11-19

  Uribarri, Jaime ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Bone disease; Cardiovascular disease; Chronic kidney disease; Hyperparathyroidism; Nutrition

Indexed keywords

CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR; NITRIC OXIDE; PARATHYROID HORMONE; PHOSPHORUS; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR PIT 1;

ARTICLE; BIOAVAILABILITY; BONE DISEASE; BONE MASS; BONE REMODELING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY CALCIFICATION; CREATININE BLOOD LEVEL; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; FOOD INTAKE; GENE OVEREXPRESSION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; INTESTINE ABSORPTION; KIDNEY CALCIFICATION; KIDNEY DISEASE; KIDNEY FAILURE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRESCRIPTION; PROTEIN INTAKE; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; STEADY STATE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ATHEROSCLEROSIS; BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; HYPERPARATHYROIDISM; NUTRITION;

ATHEROSCLEROSIS; BONE DISEASES; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; HYPERPARATHYROIDISM; PHOSPHATES; PHOSPHORUS, DIETARY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84885468407     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12201     Document Type: Article

References (42)

1. Slatopolsky, E., S. Caglar, L. Gradowska, et al. 1972. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int. 2: 147-151.
2. Sprague, S.M. 2010. Renal bone disease. Curr. Opin. Endocrinol. Obes. 17: 535-539.
3. Block, G.A., T.E. Hulbert-Shearon, N.W. Levin & F.K. Port 1998. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 31: 607-617.
4. Kestenbaum, B., J.N. Sampson, K.D. Rudser, et al. 2005. Serum phosphate levels and mortality risk among persons with chronic kidney disease. J. Am. Soc. Nephrol. 16: 520.
5. Bellasi, A. et al. 2011. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin. J. Am. Soc. Nephrol. 6: 883-891.
6. Chue, C.D. et al. 2012. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 98: 219-224.
7. Tuttle, K. & R. Short 2009. Longitudinal relationships among coronary artery calcification, serum phosphorus and kidney function. Clin. J. Am. Soc. Nephrol. 4: 1968-1973.
8. Toussaint, N.D. et al. 2008. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol. Dial. Transplant 23: 586-593.
9. Palmer, S.C. et al. 2011. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. J. Am. Med. Assoc. 305: 1119-1127.
10. O'Seaghdha, C.M., S.J. Hwang, P. Muntner, et al. 2011. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Serum Phosphorus predicts incident CKD and ESRD. Nephrol. Dial. Transplant 26: 2885.
11. Schwarz, S. et al. 2006. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 1: 825-831.
12. Zocali, C. et al. 2011. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J. Am. Soc. Nephrol. 22: 1923-1930.
13. Chue, C.D. et al. 2011. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrol. Dial. Transplant 26: 2576-2582.
14. Voormolen, N. et al. 2007. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial. Transplant 22: 2909-2916.
15. Dusso, A. et al. 2006. Pathogenetic mechanisms of parathyroid hyperplasia. Kidney Int. Suppl. 102: S8-S11.
16. Fukagawa, M., H. Komaba & T. Kakuta 2013. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy. Expert Opin. Pharmacother. 14: 863-871.
17. Adragao, T. et al. 2012. Ankle-brachial index, vascular calcifications and mortality in dialysis patients. Nephrol. Dial. Transplant 27: 318-325.
18. Gutierrez, O.M. et al. 2008. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359: 584-592.
19. Moe, S., T. Drueke, N. Lameire & G. Eknoyan 2007. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv. Chronic Kidney Dis. 14: 3-12.
20. Shuto, E. et al. 2009. Dietary phosphorus acutely impairs endothelial function. Clin. J. Am. Soc. Nephrol. 20: 1504-1512.
21. Ibels, L.S. et al. 1978. Preservation of function in experimental renal disease by dietary restriction of phosphate. N. Engl. J. Med. 298: 122-126.
22. Haut, L.L. et al. 1980. Renal toxicity of phosphate in rats. Kidney Int. 17: 722-731.
23. Loghman-Adham, M. 1993. Role of phosphate retention in the progression of renal failure. J. Lab Clin. Med. 122: 12-25.
24. Sekiguchi, S. et al. 2011. Phosphate overload induces podocyte injury via type III Na-dependent phosphate transporter. Am. J. Physiol. Renal Physiol. 300: F848-F856.
25. Sim, J.J. et al. 2013. Phosphorus and risk of renal failure in subjects with normal renal function. Am. J. Med. 126: 311-318.
26. Mehrotra, R. et al. 2013. No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int. DOI: 10.1038/ki.2013.145.
27. Sullivan, C. et al. 2009. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. J. Am. Med. Assoc. 301: 629-635.
28. Qunibi, W.Y. et al. 2004. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE) Study. Kidney Int. 65: 1914-1926.
29. Savica, V. et al. 2009. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J. Am. Soc. Nephrol. 20: 639-644.
30. de Boer, I.H., T.C. Rue & B. Kestenbaum 2009. Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kid. Dis. 53: 399.
31. Portale, A.A., B.P. Halloran & R.C. Morris, Jr. 1989. Physiologic regulation of the serum concentration of 1, 25-dihydroxyvitamin D by phosphorus in normal men. J. Clin. Invest. 83: 1494.
32. Calvo, M.S. & J. Uribarri 2013. Contributions to total phosphorus intake: all sources considered. Semin. Dial 26: 54-61.
33. Calvo, M.S. & J. Uribarri In press. The public health impact of dietary phosphorus excess on bone and cardiovascular health in the general population. Am. J. Clin. Nutr. DOI: 10.3945/ajcn.112.053934.
34. Moe, S.M. et al. 2011. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6: 257-264.
35. Kemi, V.E. et al. 2010. Low calcium:phosphorus ratio in habitual diets affects serum parathyroid hormone concentration and calcium metabolism in healthy women with adequate calcium intake. Br. J. Nutr. 103: 561-568.
36. Alonso, A., J.A. Nettleton, J.H. Ix, et al. 2010. Dietary phosphorus, blood pressure and incidence of hypertension in the Atherosclerosis Risk in Communities (ARIC) Study and the Multi-Ethnic Study of Atheosclerosis (MESA). Hypertension 55: 776-784.
37. Calvo, M.S., R. Kumar & H. Heath 1990. Persistently elevated parathyroid hormone secretion and action in young women after four weeks of ingesting high phosphorus, low calcium diets. J. Clin. Endo. Metab. 70: 1334.
38. Ferrari, S.L., J.P. Bonjour & R. Rizzoli 2005. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90: 1519.
39. Antoniucci, D.M., T. Yammashita & A.A. Portale 2006. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 91: 3144.
40. Burnett, S.M., S.C. Gunawardene, F.R. Bringhurst, et al. 2006. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Metab. 21: 1187.
41. Vervloet, M.G., F.J. van Ittersum, R.M. Büttler, et al. 2011. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin. J. Am. Soc. Nephrol. 6: 383.
42. Yamamoto, K.T. et al. 2013. Dietary phosphorus is associated with greater left ventricular mass. Kidney Int. 83: 707-714.